Hypofractionated radiotherapy in prostate cancer

Abstract

In regards to prostate cancer, the classic radiotherapy dose ranges from 70-80 Gy, administered in daily 2-Gy fractions. However, when taking into account the particular radiobiological model of prostate cancer cells, one realizes that there is a potential theoretical advantage to delivering a greater biological effective dose per treatment in a lower number of fractions. Both recent and older publications have attempted to explore this treatment option. This critical review comprehensively examines the current state of knowledge concerning hypofractionated radiotherapy in prostate cancer.

The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis

“…1 Published randomized controlled trials support the use of radiotherapy in the primary 2 and postoperative 3 settings, with other randomized controlled trials assessing appropriate dosing of external-beam radiotherapy 4 and the concomitant use of hormonal therapy. 5 Alternatives to dose-escalated external-beam radiotherapy include lowdose-rate (LDR) 6 and high-dose-rate (HDR) 7 brachytherapy (with or without integrated external-beam radiation therapy), hypofractionated radiation therapy, 8 stereotactic body radiation therapy, 9 and particle therapy. 10 Various clinical trials have been initiated to further define best practices for the use of radiotherapy either alone or in combination with other treatments.…”

Factores que influyen en la indicación del tratamiento del cáncer de próstata organoconfinado

“…Diversos estudios preclínicos sugieren que el cáncer de próstata difiere de la mayoría de otros tumores y el uso de radioterapia hipofraccionada se justifica por el hecho de que existe una relación dosis-respuesta y una alta sensibilidad a la dosis por fracción aplicada (203). La RT hipofraccionada podría ser más ventajosa que la RT convencional, ya que permitiría mejorar el control tumoral y reducir las toxicidades radioinducidas.…”